Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients
- 1 February 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 111 (4), 412-419
- https://doi.org/10.1161/01.cir.0000153810.81187.7d
Abstract
Background— Soluble CD40L (sCD40L), a substance that maximally reflects in vivo platelet activation, is increased in patients with hypercholesterolemia. We investigated the relation between sCD40L and platelet CD4OL in hypercholesterolemic patients before and after a short-term treatment with atorvastatin. Methods and Results— Collagen-induced platelet CD40L and plasma levels of sCD40L and prothrombin fragment F1+2, a marker of thrombin generation, were investigated in 30 hypercholesterolemic patients and 20 healthy subjects. Hypercholesterolemic patients were then randomized to either diet (n=15; group A) or atorvastatin 10 mg/d (group B); the aforementioned variables were measured at baseline and after 3 days of treatment. Compared with referents, hypercholesterolemic patients showed higher values of platelet CD40L (PPPPPPPPConclusions— This study shows that, in hypercholesterolemia, platelet overexpression of CD40L may account for enhanced plasma levels of sCD40L and F1+2. Atorvastatin exerts a direct antithrombotic effect via inhibition of platelet CD40L and CD40L-mediated thrombin generation, independently of its cholesterol-lowering effect.This publication has 30 references indexed in Scilit:
- Platelet storage solution effects on the accuracy of laboratory tests for platelet function: a multi‐laboratory studyVox Sanguinis, 2004
- Soluble CD40LCirculation, 2003
- Statins differ in their ability to block NF-kB activation in human blood monocytesInternational journal of clinical pharmacology and therapeutics, 2003
- CD40-CD40L and Platelet FunctionCirculation Research, 2003
- Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular CellsCirculation, 2002
- Association Between Enhanced Soluble CD40L and Prothrombotic State in HypercholesterolemiaCirculation, 2002
- Induction of Tissue Factor Expression in Human Endothelial Cells by CD40 Ligand Is Mediated via Activator Protein 1, Nuclear Factor κB, and Egr-1Published by Elsevier BV ,2002
- Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARα/RXRα and Decrease the Transactivation of NFκBBiochemical and Biophysical Research Communications, 2002
- Pharmacodynamics and Pharmacokinetic-Pharmacodynamic Relationships of Atorvastatin, an HMG-CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 2000
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998